Want to see ALXO full AI Analyst Report?
ALXO Stock Chart & Stats
$1.67
$0.01(0.54%)
At close: 4:00 PM EST
$1.67
$0.01(0.54%)
Day’s Range― - ―
52-Week Range$0.40 - $2.66
Previous CloseN/A
Volume579.15K
Average Volume (3M)1.22M
Market Cap
$278.55M
Enterprise Value$168.05M
Total Cash (Recent Filing)$140.32M
Total Debt (Recent Filing)$5.22M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding134,562,910
10 Day Avg. Volume1,483,231
30 Day Avg. Volume1,220,227
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.72
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.12K
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$4.67Price Target Upside179.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reproducible Biomarker-driven EfficacyIndependent Phase II data show consistent, high response rates in CD47‑overexpressing subsets across indications, supporting a biomarker‑enriched development strategy. This reproducibility improves the odds of a targeted registrational path and more efficient trials if the CDx is prospectively validated.
Durable Responses And Safety DatabaseLong median durations of response indicate sustained clinical benefit consistent with an immuno‑oncology mechanism, while a large safety dataset (>800 patients) reduces unknown toxicities. Together these strengthen regulatory discussions, labeling prospects and partner interest over the medium term.
Stronger Leadership And FinancingAdding seasoned development and legal leadership plus a secured $50M facility and debt refinancing materially improves execution capacity and near‑term runway. This bolsters ability to run registrational trials, negotiate partnerships and manage regulatory complexity over the next 12–24 months.
Bears Say
Pre‑revenue, Recurring LossesAs a development‑stage biotech with no commercial revenue, ALXO depends on external capital to fund operations. Ongoing large losses erode equity and increase dilution risk, making long‑term program execution and independence contingent on successful financings or partnerships.
Material Negative Cash Flow And BurnPersistent negative operating and free cash flow requires continued access to capital. Even with recent financing, structured loan covenants and sizable burn constrain strategic flexibility, may force dilution or milestone‑contingent financing, and heighten execution risk for registrational efforts.
Biomarker And Sample‑size UncertaintyKey efficacy signals derive from very small subgroups and retrospective CD47 thresholds, raising risk that prospective assay/ cutoff work may shrink the eligible population. This complicates trial design, regulatory acceptance and commercial addressable market estimates until validated in larger, prospective studies.
ALX Oncology Holdings News
ALXO FAQ
What was Alx Oncology Holdings, Inc.’s price range in the past 12 months?
Alx Oncology Holdings, Inc. lowest stock price was $0.40 and its highest was $2.66 in the past 12 months.
What is Alx Oncology Holdings, Inc.’s market cap?
Alx Oncology Holdings, Inc.’s market cap is $278.55M.
When is Alx Oncology Holdings, Inc.’s upcoming earnings report date?
Alx Oncology Holdings, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 36 days.
How were Alx Oncology Holdings, Inc.’s earnings last quarter?
Alx Oncology Holdings, Inc. released its earnings results on May 08, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.188 by $0.018.
Is Alx Oncology Holdings, Inc. overvalued?
According to Wall Street analysts Alx Oncology Holdings, Inc.’s price is currently Undervalued.
Does Alx Oncology Holdings, Inc. pay dividends?
Alx Oncology Holdings, Inc. does not currently pay dividends.
What is Alx Oncology Holdings, Inc.’s EPS estimate?
Alx Oncology Holdings, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Alx Oncology Holdings, Inc. have?
Alx Oncology Holdings, Inc. has 134,562,910 shares outstanding.
What happened to Alx Oncology Holdings, Inc.’s price movement after its last earnings report?
Alx Oncology Holdings, Inc. reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.188. Following the earnings report the stock price went up 11.23%.
Which hedge fund is a major shareholder of Alx Oncology Holdings, Inc.?
Currently, no hedge funds are holding shares in ALXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ALX Oncology Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.67 (179.44% Upside)
$4.67 (179.44% Upside)
Hedge Fund Trend
Increased
By 23.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
443.20%
12-Months-Change
Fundamentals
Return on Equity
-124.06%
Trailing 12-Months
Asset Growth
47.50%
Trailing 12-Months
Company Description
Alx Oncology Holdings, Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
ALXO Company Deck
ALXO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful, reproducible efficacy signals for evorpacept combinations—especially in CD47-high, centrally confirmed HER2-positive patients—with durable responses across independent studies, a large evorpacept safety database, progressing second program (ALX2004), and strengthened corporate resources. However, the clinical findings are preliminary given small exploratory cohorts, CD47 assay/cutoff uncertainty, discordant HER2 testing, and anticipated need for a registrational trial, which introduces execution and regulatory risk. Overall, momentum and positive clinical signals outweigh the limitations, but important validation and prospective biomarker work remain.View all ALXO earnings summariesALXO Stock 12 Month Forecast
Average Price Target
$4.67
▲(179.44% Upside)
Technical Analysis
Ownership Overview
10.06% Insiders
3.58% Mutual Funds
55.50% Other Institutional Investors
24.72% Public Companies and
Individual Investors